Literature DB >> 8881446

Petrosal sinus sampling for diagnosis of Cushing's disease: evidence of false negative results.

J López1, B Barceló, T Lucas, F Salame, C Alameda, M Boronat, L Salto, J Estrada.   

Abstract

OBJECTIVE: While inferior petrosal sinus (IPS) sampling correctly diagnoses pituitary-dependent Cushing's syndrome if a significant ratio of plasma ACTH between the IPS and the peripheral blood is demonstrated, little has been said about the significance of a negative ratio in Cushing's disease (e.g. a false-negative result). This study evaluates the results of IPS sampling in patients with Cushing's disease, and compares them with both imaging findings and transsphenoidal examination.
DESIGN: The results of IPS sampling were retrospectively compared with both imaging findings and transsphenoidal examination. IPS samples were obtained before and 2, 5 and 10 minutes after intravenous administration of 100 micrograms of CRH. PATIENTS: Thirty-two patients with Cushing's disease were evaluated. All subsequently underwent transphenoidal examination of the pituitary gland. MEASUREMENTS: The ratio of the ACTH concentrations at the IPS and in the peripheral blood (IPS:P ratio), and the ratio of the ACTH concentrations between the IPSs (interpetrosal ratio) were calculated. Radiographic evaluation of the pituitary gland was performed with magnetic resonance imaging (MRI, 29 cases) or computed tomography imaging (CT, 3 cases).
RESULTS: Transsphenoidal examination of the pituitary gland revealed a microadenoma in 27 cases. Radiological imaging showed a signal compatible with a microadenoma in 22 cases (68.8%), and correctly located the tumour at the side found at surgery in 14 of the 22 cases with positive transsphenoidal findings (MRI 13 cases, CT 1 case, overall 63.6%). Successful bilateral catheterization was accomplished in 30 patients (93.8%). Samples before and after CRH stimulation were drawn in 24 cases. No major complications were observed with the technique. IPS catheterization correctly predicted Cushing's disease (by means of a significant IPS: P ACTH ratio) in 27 of the 30 patients (90%) with basal sampling, and in 23 of the 24 cases with samples drawn before and after CRH administration (95.8%). Taking into account the 12 patients with a lateral microadenoma shown at transsphenoidal examination, IP sinus ACTH ratio was in agreement with the side recorded by the neurosurgeon in 8/12 cases (66.7%). MRI correctly located the tumour in 8/12 patients (66.7%). One patient showed no significant IPS: P ACTH ratio in any set of samples. His MRI showed no sign of a microadenoma. Two years later, another pituitary MRI evaluation showed a midline hypodense signal. The transsphenoidal examination revealed a microadenoma and the post-operative plasma cortisol and urinary free cortisol fell to 293 nmol/l and 100 nmol/24 h, respectively.
CONCLUSIONS: Only when a significant IPS:P ACTH ratio is present can Cushing's disease be established by IPS sampling. The absence of a significant IPS: P ACTH ratio does not necessarily imply ectopic secretion of ACTH, nor does it exclude Cushing's disease. The results of lateralization by IPS sampling do not remove the need for a thorough transsphenoidal examination of the contents of the sella turcica.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8881446     DOI: 10.1046/j.1365-2265.1996.d01-1550.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  19 in total

Review 1.  Neurology of the pituitary gland.

Authors:  J R Anderson; N Antoun; N Burnet; K Chatterjee; O Edwards; J D Pickard; N Sarkies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

Review 2.  Neuroendocrine imaging.

Authors:  D J Seidenwurm
Journal:  AJNR Am J Neuroradiol       Date:  2008-03       Impact factor: 3.825

Review 3.  Is prolactin measurement of value during inferior petrosal sinus sampling in patients with adrenocorticotropic hormone-dependent Cushing's Syndrome?

Authors:  S T Sharma; L K Nieman
Journal:  J Endocrinol Invest       Date:  2013-07-26       Impact factor: 4.256

4.  Clinical manifestations and hormonal profile of two women with Cushing's disease and mild deficiency of 21-hydroxylase.

Authors:  M Boronat; A Carrillo; A Ojeda; J Estrada; B Ezquieta; F Marín; F J Nóvoa
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 5.  Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

Authors:  Avital Perry; Christopher Salvatore Graffeo; Christopher Marcellino; Bruce E Pollock; Nicholas M Wetjen; Fredric B Meyer
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-24

6.  Selective use of bilateral inferior petrosal sinus sampling in patients with adrenocorticotropin-dependent Cushing's syndrome prior to transsphenoidal surgery.

Authors:  Sigrid Jehle; Jane E Walsh; Pamela U Freda; Kalmon D Post
Journal:  J Clin Endocrinol Metab       Date:  2008-09-16       Impact factor: 5.958

7.  Prolactin as a marker of successful catheterization during IPSS in patients with ACTH-dependent Cushing's syndrome.

Authors:  S T Sharma; H Raff; L K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2011-10-26       Impact factor: 5.958

8.  Intraoperative optical identification of pituitary adenomas.

Authors:  M Sam Eljamel; Graham Leese; Harry Moseley
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

9.  Inferior petrosal sinus ACTH and prolactin responses to CRH in ACTH-dependent Cushing's syndrome: a single centre experience from the United Kingdom.

Authors:  Christina Daousi; Thomas Nixon; Mohsen Javadpour; Katharine Hayden; Ian A MacFarlane
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

10.  The impact of cavernous sinus drainage pattern on the results of venous sampling in patients with suspected cushing syndrome.

Authors:  N Hayashi; M Kurimoto; M Kubo; N Kuwayama; K Kurosaki; S Nagai; S Endo
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-09       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.